FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1498 May 9, 2002 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Schiller and colleagues (Jan. 10 issue)¹ report equivalent overall survival and response rates for four third-generation chemotherapy regimens in advanced non–small-cell lung cancer. The median survival in the four groups was 7.4 to 8.1 months. In a disease with such a poor prognosis, quality of life and control of symptoms are relevant end points, but neither of these end points was mentioned, nor were hospitalization rates or costs reported. Assuming that four cycles of the regimen are given during a three-to-four-month period, that the body-surface area is 1.7 m², and that the glomerular-filtration rate is 75 . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.